|
Volumn 3, Issue 8, 2006, Pages 420-421
|
ASSENT-4 PCI: Should facilitated percutaneous coronary intervention be used in clinical practice?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ABCIXIMAB;
FIBRINOGEN RECEPTOR ANTAGONIST;
FIBRINOLYTIC AGENT;
RETEPLASE;
TENECTEPLASE;
ANGIOGRAPHY;
BLEEDING;
BLOOD CLOT LYSIS;
CLINICAL PRACTICE;
CLINICAL RESEARCH;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
FIBRINOLYSIS;
HEART INFARCTION;
HEART MUSCLE REPERFUSION;
HUMAN;
INTERMETHOD COMPARISON;
MAXIMUM PERMISSIBLE DOSE;
MORTALITY;
OPEN STUDY;
PERCUTANEOUS CORONARY INTERVENTION;
PRIORITY JOURNAL;
RISK ASSESSMENT;
SHORT SURVEY;
ST SEGMENT ELEVATION;
SYSTEMATIC ERROR;
TREATMENT CONTRAINDICATION;
TREATMENT OUTCOME;
VASCULAR PATENCY;
|
EID: 33746657994
PISSN: 17434297
EISSN: 17434300
Source Type: Journal
DOI: 10.1038/ncpcardio0626 Document Type: Short Survey |
Times cited : (1)
|
References (5)
|